Manal Bel Imam

Manal Bel Imam

Auto-generated profile, based on publicly available information

Manal Bel Imam

Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
IOIsmail Ogulur
Ismail Ogulur
YMYasutaka Mitamura
Yasutaka Mitamura
DYDuygu Yazici
Duygu Yazici
YPYagiz Pat
Yagiz Pat
Sena ArdicliSena Ardicli
Sena Ardicli
CACezmi A. Akdis
Cezmi A. Akdis
Significant advancements have been made in understanding the cellular and molecular mechanisms of type 2 immunity in allergic diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, eosinophilic esophagitis (EoE), food and drug allergies, and atopic dermatitis (AD). Type 2 immunity has evolved to protect against parasitic diseases and toxins, plays a role in the expulsion of parasites and larvae from inner tissues to the lumen and outside the body, maintains microbe-rich skin and mucosal epithelial barriers and counterbalances the type 1 immune response and its destructive effects. During the development of a type 2 immune response, an innate immune response initiates starting from epithelial cells and innate lymphoid cells (ILCs), including dendritic cells and macrophages, and translates to adaptive T and B-cell immunity, particularly IgE antibody production. Eosinophils, mast cells and basophils have effects on effector functions. Cytokines from ILC2s and CD4+ helper type 2 (Th2) cells, CD8 + T cells, and NK-T cells, along with myeloid cells, including IL-4, IL-5, IL-9, and IL-13, initiate and sustain allergic inflammation via T cell cells, eosinophils, and ILC2s; promote IgE class switching; and open the epithelial barrier. Epithelial cell activation, alarmin release and barrier dysfunction are key in the development of not only allergic diseases but also many other systemic diseases. Recent biologics targeting the pathways and effector functions of IL4/IL13, IL-5, and IgE have shown promising results for almost all ages, although some patients with severe allergic diseases do not respond to these therapies, highlighting the unmet need for a more detailed and personalized approach.

31 October 2022 in Asia Pacific Allergy
Verified
Journal Article
Open access
PDF file
JLJuan-Felipe López
Juan-Felipe López
MIManal Bel Imam
Manal Bel Imam
PSPattraporn Satitsuksanoa
Pattraporn Satitsuksanoa
SLSophieke Lems
Sophieke Lems
MYMinglin Yang
Minglin Yang
WVWillem van de Veen
Willem van de Veen
Allergen-specific immunotherapy (AIT) is considered the only curative treatment for allergic diseases mediated by immunoglobulin E (IgE). Currently, the route of administration depends both on the different types of causal allergens and on its effectiveness and safety profile. Several studies have reported the mechanisms and changes in humoral and cellular response underlying AIT; however, the full picture remains unknown. Knowledge of who can benefit from this type of treatment is urgently needed due to the patient safety risks and costs of AIT. In vivo or in vitro biomarkers have become a strategy to predict clinical outcomes in precision medicine. There are currently no standardized biomarkers that allow determining successful responses to AIT, however, some studies have found differences between responders and nonresponders. In addition, different candidates have been postulated that may have the potential to become biomarkers. In this review, we aim to summarize the findings to date related to biomarkers in different IgE-mediated allergic diseases (respiratory, food, and venom allergy) with the potential to define who will benefit from AIT.

14 April 2025 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
MIManal Bel Imam
Manal Bel Imam
SISayuri Iwasaki
Sayuri Iwasaki
SLSophieke Lems
Sophieke Lems
LCLacin Cevhertas
Lacin Cevhertas
PWPatrick Westermann
Patrick Westermann
SGSwiss EoE Cohort Study Group
Swiss EoE Cohort Study Group
Introduction: Eosinophilic esophagitis (EoE) is a chronic inflammatory condition with an incompletely understood immuno‐pathogenesis involving a T2 response. EoE is triggered by food allergens although, unlike IgE‐mediated allergies, it exhibits high IgG4 levels in oesophageal biopsies and in circulation. We investigated whether other antibody isotypes specific for food allergens are elevated in EoE and vary with disease activity.Methods: Plasma samples from patients with active EoE (n = 51), inactive EoE (n = 82) and non‐EoE controls (n = 14) were analysed for food‐specific IgG and IgA subclasses against casein, whey, wheat, egg and individual cow's milk allergens by ELISA. α‐lactalbumin (Bos d 4)‐ and β‐lactoglobulin (Bos d 5)‐specific B cells were measured by flow cytometry in a subset of patients.Results: Food allergen‐specific antibodies in the plasma varied across EoE subgroups and non‐EoE controls. Elevated IgG4 in EoE patients confirmed a strong antibody response to food allergens, including casein, wheat and egg. αS1‐casein (Bos d 9)‐specific IgG, IgG2, IgG4, IgA1 and IgA2 differed between EoE and non‐EoE controls and between active and inactive EoE. β‐casein (Bos d 11, A1 variant) measurements showed higher levels of specific IgG2 and IgG4 in both EoE groups, whereas whey‐derived allergens showed opposing responses: Bos d 4 responses favoured IgG4, and Bos d 5 responses were elevated across multiple IgG and IgA subclasses in EoE. Allergen‐specific B cells could not be isolated from the circulation.Conclusion: Our findings reveal distinct antibody profiles in EoE plasma, with elevated IgG and IgA subclasses beyond IgG4, highlighting a complex immune response to food allergens. Differential antibody responses support their clinical relevance in dietary management strategies, while the absence of allergen‐specific B cells in circulation likely restricts antibody production to the inflamed oesophagus. Future research should explore whether these antibody profiles can guide personalised treatment and novel therapeutic targets in EoE.

8 March 2023 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
MIManal Bel Imam
Manal Bel Imam
CSCharalampos‐Vlasios Stikas
Charalampos‐Vlasios Stikas
PGPayal Guha
Payal Guha
BCBo L. Chawes
Bo L. Chawes
DCDerek Chu
Derek Chu
CCCore Outcome Measures for Food Allergy (COMFA) consortium
Core Outcome Measures for Food Allergy (COMFA) consortium
BackgroundMixed and non-IgE-mediated food allergy is a subset of immune-mediated adverse food reactions that can impose a major burden on the quality of life of affected patients and their families. Clinical trials to study these diseases are reliant upon consistent and valid outcome measures that are relevant to both patients and clinicians, but the degree to which such stringent outcome reporting takes place is poorly studied. ObjectiveAs part of the Core Outcome Measures for Food Allergy (COMFA) project, we identified outcomes reported in randomized clinical trials (RCT) of treatments for mixed or non-IgE-mediated food allergy. DesignIn this systematic review, we searched the Ovid, MEDLINE and Embase databases for RCTs in children or adults investigating treatments for food protein-induced enterocolitis syndrome, food protein-induced allergic proctocolitis, food protein-induced enteropathy and eosinophilic gastrointestinal disorders including eosinophilic esophagitis [EoE], eosinophilic gastritis and eosinophilic colitis published until 14 October 2022. ResultsTwenty-six eligible studies were identified, with 23 focused on EoE (88%). Most interventions were corticosteroids or monoclonal antibodies. All EoE studies assessed patient-reported dysphagia, usually using a non-validated questionnaire. Twenty-two of 23 EoE studies used peak tissue eosinophil count as the primary outcome, usually using a non-validated assessment method, and other immunological markers were only exploratory. Thirteen (57%) EoE studies reported endoscopic outcomes of which six used a validated scoring tool recently recommended as a core outcome for EoE trials. Funding source was not obviously associated with likelihood of an RCT reporting mechanistic versus patient-reported outcomes. Only 3 (12%) RCTs concerned forms of food allergy other than EoE, and they reported on fecal immunological markers and patient-reported outcomes. ConclusionsOutcomes measured in clinical trials of EoE and non-IgE-mediated food allergy are heterogeneous and largely non-validated. Core outcomes for EoE have been developed and need to be used in future trials. For other forms of mixed or non-IgE-mediated food allergies, core outcome development is needed to support the development of effective treatments. Systematic review registrationOSF public registry DOI:10.17605/OSF.IO/AZX8S

1 January 2026 in Inflammatory Intestinal Diseases
Verified
Journal Article
Open access
MIManal Bel Imam
Manal Bel Imam
HDHang Du
Hang Du
ÖAÖzge Ardicli
Özge Ardicli
JMJenne Meinema
Jenne Meinema
WVWillem van de Veen
Willem van de Veen
Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disease affecting the esophagus, characterized by esophageal dysfunction, dysphagia, and tissue remodeling, leading to significant impairment in quality of life. The pathogenesis of EoE involves a complex interplay of genetic, environmental, and immunological factors. Although the disease is strongly associated with type 2 immune responses, emerging evidence suggests that B cells and antibody responses, particularly IgG4, also play a crucial role in disease development and progression. Summary: This review explores the pathogenesis of EoE with a focus on the role of B cells, plasma cells, and antibodies. Epithelial barrier dysfunction is a pivotal factor in EoE, influenced by genetic predisposition, environmental triggers, and immune responses. The impaired barrier allows for antigen penetration, triggering type 2 immune responses, and chronic inflammation. Elevated levels of IgG4 in esophageal tissues and their potential to drive inflammation and tissue remodeling are highlighted. Animal models and clinical studies provide insights into the involvement of B cells and antibodies in EoE, suggesting that these components may contribute to the chronic inflammatory state and disease severity. Key Messages: B cells are increasingly recognized for their role in EoE, particularly through their production of antibodies and cytokines that contribute to the inflammatory milieu. EoE is primarily driven by type 2 immune responses involving cytokines such as IL-4, IL-5, and IL-13, which promote eosinophil recruitment and chronic inflammation. Regulatory B cells, which produce anti-inflammatory cytokines such as IL-10 and IL-35, may play a role in modulating immune responses in EoE and contribute to the production of IgG4 antibodies. Elevated levels of IgG4 in esophageal tissues of EoE patients are linked to chronic inflammation and tissue remodeling, suggesting a potential role in disease pathogenesis. Further studies are needed to elucidate the specific mechanisms by which B cells and antibodies contribute to EoE.

4 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GMGiorgia Moschetti
Giorgia Moschetti
CVChiara Vasco
Chiara Vasco
FCFrancesca Clemente
Francesca Clemente
PLPaola Larghi
Paola Larghi
SMSara Maioli
Sara Maioli
JGJens Geginat
Jens Geginat
Background: Autosomal Dominant-Hyper-IgE Syndrome (AD-HIES) is caused by dominant-negative (DN) STAT3 mutations and characterized by high IgE levels, a lack of Th17-cells and recurrent infections with extracellular pathogens. We previously identified an enigmatic population of IL-10 producing CCR6 + B-helper T-cells and investigated here their relationship to Th17-cells and STAT3 signalling requirements. Methods: Human blood lymphocytes were analysed by multiparametric flow cytometry in healthy donors and AD-HIES patients. Analysis was performed by conventional gating or with bioinformatic tools. FACS-purified T-cell subsets were activated in vitro and Th17 differentiation assessed. T-cell antigen specificities were assessed by activation with heat-killed pathogens or antigenic peptide pools. B helper capacities were determined according to antibody secretion in B-T co-cultures by ELISA. Results: CCR6 + Th-cells that lacked subset-defining differentiation markers were mostly non-polarised central memory T-cells (T CM ) that produced IL-10 and expressed RORγt. They were pre-committed to a Th17 fate, since TCR stimulation in the absence of polarising cytokines induced efficient Th17 differentiation. The latter was promoted by an autocrine loop of STAT3-activating cytokines. CCR6 + Th-cells were reduced in patients with DN-STAT3 mutations but contained activated CCR6 + T CM that produced IL-10 and responded vigorously to AD-HIES-associated pathogens. These residual CCR6 + Th-cells provided B-cell help for IgG and IgE production. Conclusions: Th17 differentiation in AD-HIES patients was not completely impaired but arrested at an intermediate stage of IL-10 producing “pre-Th17”-cells. Surprisingly, DN-STAT3 mutations did not inhibit IL-10 production by CD4 + T-cells. Pre-Th17-cells were activated by AD-HIES-associated pathogens and possessed B-helper functions, suggesting that they are not protective but promote aberrant IgE production.